[Berlin, Germany – 28 October 2019]
GARDP is pleased to announce continued support from the Dutch Ministry of Health, Welfare and Sport. The funding of €5 million will be used to support GARDP’s efforts to develop new treatments for drug-resistant infections and to ensure sustainable access, promoting responsible use and affordability to all in need.
[Berlin, Germany – 28 October 2019]
Today the UK government announced £3.5 million of funding to develop new treatments for gonorrhoea. It will enable global access, including in low-and middle-income countries (LMICs) where the burden of antimicrobial resistance (AMR) is greatest.
[Geneva, Switzerland – 28 October 2019]
Today, GARDP unveiled its strategy to deliver five new treatments that address urgent drug-resistant infections by 2025 at the World Health Summit. Uniting against antibiotic resistance: delivering 5 BY 251 sets out how GARDP plans to develop new treatments for bacterial infections, safeguarding their sustainable access so they are available to everyone, everywhere.
[Geneva, Switzerland – 22 October 2019]
The Global Antibiotic Research and Development Partnership (GARDP) announced today that Prof Veronika von Messling has joined the Board as its newest member, with Dr Prabhavathi Fernandes selected as Chair of the Scientific Advisory Committee, bringing an exceptional level of international leadership and experience.
[Geneva, Switzerland and Waltham, USA – 19 August 2019]
The Global Antibiotic Research and Development Partnership (GARDP), a not for profit organisation developing new treatments for drug resistant infections, and Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today jointly announced the initiation of a global phase 3 pivotal trial of zoliflodacin. Zoliflodacin is a novel, first-in-class oral antibiotic being developed for the treatment of gonorrhoea.
[Geneva – 19 August 2019]
GARDP and FIND welcome the Australian Minister for Education’s announcement of $5m to establish an Australian Research Council (ARC) Research Hub to Combat Antimicrobial Resistance, which will be led by the Kirby Institute.
[Geneva – 26 June 2019]
GARDP calls upon the global community to work with it to develop and deliver 5 new treatments by 2025 to address the most urgent public health needs
Today GARDP announces its ‘5 BY 25’ goal to deliver five new treatments in response to the growing global threat of antimicrobial resistance (AMR). GARDP’s five treatments will focus on the priority bacterial pathogens identified by the World Health Organization (WHO).
[Geneva – 23 May 2019]
GARDP is pleased to announce funding of €400,000 from the Government of the Principality of Monaco. This grant is being formalized at the 2019 World Health Assembly, where antimicrobial resistance (AMR) is a priority topic.
[Geneva – 23 May 2019]
DNDi and GARDP welcome the adoption of the resolution on AMR and call for continued political commitment at the highest level, including at the UN High-Level Meeting on Universal Health Coverage at the UN General Assembly in September.
[Geneva/San Francisco/Brisbane/Saarbrücken – 11 April 2019]
GARDP is partnering with Calibr, HIPS, and CO-ADD in its efforts to develop and ensure new antibiotics are globally available to all patients who need them.
[Geneva – 2 April 2019]
GARDP is now an independent legal entity following a successful three-year incubation, hosted by the Drugs for Neglected Diseases initiative (DNDi). During this time, GARDP has already begun working with partners to develop antibiotics to tackle drug-resistant infections which pose a threat to global health and development, including the achievement of the Sustainable Development Goals.
[Geneva/Hamburg – 19 March 2019]
GARDP and Evotec AG are announcing the formation of a new strategic public-private partnership to tackle the growing threat of antimicrobial resistance (AMR). By joining forces, Evotec and GARDP will leverage their capabilities and networks to address drug-resistant bacterial infections.
[Geneva/Padova – 4 March 2019]
GARDP and Penta, the paediatric infectious diseases research network, have joined forces to tackle drug-resistant infections in children. The strategic collaboration aims to accelerate paediatric development of antibiotic treatments including: clinical trials designed to meet regulatory requirements; and trials with a focus on public health interventions to inform treatment guidelines.
[Geneva – 31 January 2019]
DNDi and GARDP call for move from discussion of principles to practical guidance on ensuring access and stewardship of new and existing antibiotics at AMR discussion.
[Geneva – 4 January 2019]
Funding supports developing antibiotics for important global health priorities
GARDP is pleased to receive a EUR 1.5 million investment from the German Federal Ministry of Health (MOH). This funding is already contributing to GARDP’s efforts to develop antibiotics for drug-resistant infections including sexually-transmitted infections and newborns with sepsis – both important global health priorities. The investment also supports GARDP’s growth as its incubation period, hosted by DNDi, comes to an end.
[Liverpool, Geneva – 18 December 2018]
The University of Liverpool has signed a collaborative research agreement with GARDP in a bid to develop new treatment options for newborns with sepsis. The research seeks to explore the correct dose and frequency of potential antibiotic combinations that could improve treatment outcomes in this vulnerable population.
[Tokyo/Geneva – 12 December 2018]
First multi-actor partnership tests chemical compounds for antibacterial activity
GARDP, Eisai, and Takeda have signed an agreement for GARDP to access and screen components of Eisai and Takeda’s chemical libraries. Both libraries will be tested by the Institut Pasteur Korea in the hope of discovering novel compounds with antibacterial activity. This multi-partner agreement supports GARDP’s efforts to tackle serious bacterial infections by developing antibiotics while endeavouring to ensure their sustainable access.
배포일: 2018년 12월 12일
GARDP-에자이-다케다제약, 다자간 글로벌 파트너십 맺고 화합물 항균력 테스트 착수
한국파스퇴르연구소(소장: 류왕식)는 글로벌 항생제 연구개발 비영리 국제단체 (Global Antibiotic Research & Development Partnership, 이하 GARDP)와 일본계 글로벌 제약사들이 진행하는 새로운 항생제 개발 연구에 참여한다. GARDP는 최근 일본 글로벌 제약사 에자이(Eisai Co., Ltd., 이하 에자이), 다케다제약(Takeda Pharmaceutical Company Limited, 이하 다케다제약)과 항생제 개발 연구를 위한 다자간 파트너십 협약을 맺고 두 제약사가 제공하는 화합물 라이브러리를 활용한 항생제 개발 연구를 착수하였으며, 한국파스퇴르연구소 연구팀은 자체 구축된 초고속 약효검색 시스템을 이용하여 화합물 라이브러리로부터 항균물질 도출 및 검증 연구를 수행한다.
[4 December 2018]
Researchers analyzing the sales of oral antibiotics for children in 70 high- and middle-income countries found that consumption varies widely from country to country with little correlation between countries’ wealth and the types of antibiotics. Of concern is the relatively low-level use of amoxicillin, an antibiotic to treat the most common childhood infections. In addition, the review found the sale of antibiotics which should only be used for specific indications, or ‘Watch’ antibiotics in a quarter of all countries accounted for 20% of total antibiotic consumption. This is of concern since there is a higher risk of bacteria developing resistance to ‘Watch’ antibiotics.
[Geneva – 7 November 2018]
Results of a phase II clinical trial evaluating the safety and efficacy of zoliflodacin in patients with uncomplicated gonorrhoea have been published in the New England Journal of Medicine today. The data show zoliflodacin, an oral antibiotic, was well-tolerated and achieved very high microbiological cure rates, at urogenital sites, in patients with uncomplicated gonorrhoea.